Advertisement
Screener

REPLIGEN CORP (RGEN) Increase (Decrease) in Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

REPLIGEN CORP Increase (Decrease) in Other Operating Liabilities

REPLIGEN CORP (RGEN) reported Increase (Decrease) in Other Operating Liabilities of -$207.39 thousand for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-08-11.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2014-08-11

  • REPLIGEN CORP increase (decrease) in other operating liabilities for the quarter ending 2014-06-30 was -$101.17K, a 110.82% decline year-over-year.
  • REPLIGEN CORP increase (decrease) in other operating liabilities for the quarter ending 2014-03-31 was -$106.22K.
  • REPLIGEN CORP increase (decrease) in other operating liabilities for the quarter ending 2013-12-31 was $711.39K.
  • REPLIGEN CORP increase (decrease) in other operating liabilities for the quarter ending 2013-09-30 was $685.21K.
  • REPLIGEN CORP increase (decrease) in other operating liabilities for fiscal 2013 was $1.20M.
  • REPLIGEN CORP increase (decrease) in other operating liabilities for fiscal 2012 was -$1.11M.
  • REPLIGEN CORP increase (decrease) in other operating liabilities for fiscal 2011 was -$58.28K, a 119048.98% decline from fiscal 2010.
  • REPLIGEN CORP increase (decrease) in other operating liabilities for fiscal 2010 was $49.00.
Period endIncrease (Decrease) in Other Operating Liabilities 3 monthIncrease (Decrease) in Other Operating Liabilities 6 monthIncrease (Decrease) in Other Operating Liabilities 9 monthIncrease (Decrease) in Other Operating Liabilities 12 month
2014-06-30-$101.17K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11
-$207.39K
10-Q · filed 2014-08-11
$504.00K
derived: sum of 3 quarters · filed 2014-08-11
$1.19M
derived: sum of 4 quarters · filed 2014-08-11
2014-03-31-$106.22K
10-Q · filed 2014-05-09
$605.18K
derived: sum of 2 quarters · filed 2014-05-09
$1.29M
derived: sum of 3 quarters · filed 2014-05-09
$2.23M
derived: sum of 4 quarters · filed 2014-08-11
2013-12-31$711.39K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
$1.40M
derived: sum of 2 quarters · filed 2014-03-14
$2.33M
derived: sum of 3 quarters · filed 2014-08-11
$1.20M
10-K · filed 2014-03-14
2013-09-30$685.21K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
$1.62M
derived: sum of 2 quarters · filed 2014-08-11
$490.27K
10-Q · filed 2013-11-08
$386.13K
derived: sum of 4 quarters · filed 2014-08-11
2013-06-30$934.82K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11
-$194.94K
10-Q · filed 2014-08-11
-$299.08K
derived: sum of 3 quarters · filed 2014-08-11
-$1.52M
derived: sum of 4 quarters · filed 2014-08-11
2013-03-31-$1.13M
10-Q · filed 2014-05-09
-$1.23M
derived: sum of 2 quarters · filed 2014-05-09
-$2.45M
derived: sum of 3 quarters · filed 2014-05-09
-$2.31M
derived: sum of 4 quarters · filed 2014-05-09
2012-12-31-$104.14K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
-$1.32M
derived: sum of 2 quarters · filed 2014-03-14
-$1.18M
derived: sum of 3 quarters · filed 2014-03-14
-$1.11M
10-K · filed 2014-03-14
2012-09-30-$1.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
-$1.08M
derived: sum of 2 quarters · filed 2013-11-08
-$1.01M
10-Q · filed 2013-11-08
-$991.33K
derived: sum of 4 quarters · filed 2014-03-14
2012-06-30$141.80K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$212.76K
10-Q · filed 2013-08-07
$228.09K
derived: sum of 3 quarters · filed 2014-03-14
$231.88K
derived: sum of 4 quarters · filed 2014-03-14
2012-03-31$70.97K
10-Q · filed 2013-05-07
$86.29K
derived: sum of 2 quarters · filed 2014-03-14
$90.09K
derived: sum of 3 quarters · filed 2014-03-14
$82.45K
derived: sum of 4 quarters · filed 2014-03-14
2011-12-31$15.32K
derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14
$19.12K
derived: sum of 2 quarters · filed 2014-03-14
$11.49K
10-K · filed 2014-03-14
-$21.35K
derived: sum of 4 quarters · filed 2014-03-14
2011-09-30$3.80K
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-09
-$3.84K
10-Q · filed 2011-11-09
-$36.67K
10-Q · filed 2012-11-08
-$39.82K
derived: sum of 4 quarters · filed 2014-03-14
2011-06-30-$7.63K
10-Q · filed 2011-08-05
-$40.47K
10-Q · filed 2012-08-09
-$43.62K
derived: sum of 3 quarters · filed 2014-03-14
-$46.77K
derived: sum of 4 quarters · filed 2014-03-14
2011-03-31-$32.84K
10-Q · filed 2012-05-10
-$35.99K
derived: sum of 2 quarters · filed 2014-03-14
-$39.14K
derived: sum of 3 quarters · filed 2014-03-14
-$58.28K
10-K · filed 2013-03-15
2010-12-31-$3.15K
derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14
-$6.30K
derived: sum of 2 quarters · filed 2014-03-14
-$25.45K
10-K · filed 2014-03-14
2010-09-30-$3.15K
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-09
-$22.30K
10-Q · filed 2011-11-09
2010-06-30-$19.15K
10-Q · filed 2011-08-05
2010-03-31$49.00
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78